Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction.
To determine the cost of achieving pregnancy with different gonadotropin preparations. Cost-minimization analysis of a prospective randomized clinical trial. Twenty-two centers in six countries. Women 18 to 36 years of age with infertility for more than 1 year who were undergoing IVF or ICSI. Highly purified hMG or recombinant FSH. Mean cost of achieving an ongoing pregnancy. The mean cost per patient treatment cycle was estimated to be pound 2423 with highly purified hMG (95% CI, pound 2356 to pound 2495) and pound 2745 with recombinant FSH (95% CI, pound 2658 to pound 2830). The ongoing pregnancy rate was 22% with highly purified hMG and 19% with recombinant FSH. The cost per ongoing pregnancy was pound 10781 with highly purified hMG (95% CI, pound 9056 to pound 12919) and pound 14284 with recombinant FSH (95% CI, pound 11883 to pound 17891). Highly purified hMG and recombinant FSH are equally effective, but highly purified hMG is less expensive per cycle. Using highly purified hMG instead of recombinant FSH would translate into a 13% increase in the number of cycles that could be offered.